After an experimental treatment, a small number of persons with rectal cancer witnessed something of a miracle when their cancer simply vanished. According to the New York Times, 18 patients in a tiny clinical trial took a medicine called Dostarlimab for around six months, and by the end of it, all of their tumors had vanished.
Dostarlimab is a medication that contains laboratory-made molecules that act as replacement antibodies in the human body. The identical medicine was administered to all 18 rectal cancer patients, and as a result of the treatment, the cancer was fully eradicated in all of them, undetectable by physical examination, endoscopy, positron emission tomography or PET scans, or MRI scans.
According to the New York Times, the patients in the clinical research had previously undergone arduous therapies to eradicate their cancer, including chemotherapy, radiation, and invasive surgery, all of which could cause bowel, urinary, and even sexual problems. The 18 patients expected to have to go through them as the next step in the trial. However, they were surprised to learn that no more therapy was required.
The discoveries have caused a stir in the medical community. Dr. Alan P. Venook, a colon cancer specialist at the University of California, told the news organization that complete remission in every single patient is “unheard-of.” He lauded the study as a first of its kind in the globe. To date, 14 patients have shown the same astonishing results.
The research was published in the New England Journal of Medicine on Sunday. All of the patients had rectal cancer that had progressed locally and had an uncommon mutation known as mismatch repair deficiency (MMRd).